AbbVie's Immunogen Buy Delivers Rare Cancer Drug Approval

AbbVie's Immunogen buy delivers rare cancer drug approval

AbbVie's Decnupaz approval will give patients with rare blood cancer BPDCN an alternative to Stemline's Elzonris with a simpler dosing regimen.

AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase

AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday ...